The Role of Calcium and Magnesium in TPN Formulations

September 4, 2025

Introduction to TPN and Essential Electrolytes

Total Parenteral Nutrition (TPN) is a life-sustaining therapy for individuals unable to obtain nutrition through traditional means. This intravenous delivery of nutrients ensures patients receive essential proteins, fats, carbohydrates, vitamins, and minerals. Among these, calcium and magnesium hold critical roles, not only for bone health and muscle function but for overall metabolic stability. TPN formulations integrate these minerals to emulate the body's nutritional needs comprehensively.

Calcium and Magnesium: Essential Roles in the Human Body

What are the roles of calcium, phosphorus, and magnesium in the body?

Calcium, phosphorus, and magnesium are essential minerals that play critical roles in maintaining bone health, nerve function, and muscle contractions. Approximately 99% of calcium and 85% of phosphorus are found in the bone matrix, where they form calcium phosphate, contributing to the hardness of bones and teeth.

Roles of Calcium:

  • Vital for muscle contractions
  • Essential for blood coagulation
  • Activates enzymatic processes
  • Facilitates neurotransmitter release

Roles of Magnesium:

  • Supports muscle function and relaxation
  • Serves as a cofactor in enzymatic reactions
  • Maintains structural integrity of bones

Both minerals are regulated by hormones like vitamin D and parathyroid hormone, ensuring balanced blood levels necessary for optimal physiological function.

Implications of Imbalances

Any imbalance in these minerals can lead to significant health issues.

  • Calcium Deficiency: May result in osteoporosis, characterized by weak and brittle bones.
  • Magnesium Deficiency: Can cause neuromuscular symptoms, including muscle cramps and weakness.
  • Excess Magnesium: Risk of hypermagnesemia, leading to muscle weakness and severe cases of respiratory paralysis.

Regular monitoring and balanced intake of these minerals are crucial, especially for patients on Total Parenteral Nutrition (TPN) variations who may face altered absorption and increased requirements due to underlying medical conditions.

Recommended Electrolyte Levels in TPN

What are the recommended levels of calcium and magnesium in TPN?

In total parenteral nutrition (TPN), maintaining appropriate levels of calcium and magnesium is crucial for supporting patients’ physiological functions. The recommended dosages for these electrolytes in TPN formulations are as follows:

  • Calcium : 10 to 20 mEq per liter of TPN. This range supports muscle function and blood coagulation.
  • Magnesium : 8 to 24 mEq per liter. This electrolyte plays a vital role in neuromuscular functions and enzymatic processes, making its adequate provision critical.

Monitoring serum levels of these electrolytes ensures early detection of any imbalances that can lead to significant metabolic complications, particularly in patients unable to consume food orally.

Importance of monitoring electrolyte levels

Patients receiving TPN are particularly susceptible to shifts in electrolyte balance, which can occur due to various underlying health conditions. Regular monitoring includes checking:

  • Serum Electrolytes : Essential to prevent deficiencies like hypomagnesemia, which can present with neuromuscular symptoms.
  • Clinical Assessments : Adjustments to calcium and magnesium levels should be made based on individual needs and medical evaluations.

Additionally, understanding the interplay between calcium and magnesium during TPN can aid in minimizing complications such as metabolic bone disease and other associated disorders, highlighting the significance of accurately managing these electrolytes.

Interactions Between Calcium and Magnesium in TPN

Impact on Magnesium Metabolism

In Total Parenteral Nutrition (TPN), maintaining a delicate balance between calcium and magnesium is crucial. High-calcium additives can notably influence magnesium metabolism. Research indicates that an increase in calcium levels might result in decreased net magnesium retention and alterations in magnesium levels in bone and muscle. Specifically, when excess calcium is added to TPN solutions, it has been observed that urine magnesium concentrations increase, suggesting a shift in magnesium excretion rates.

Calcium's Influence on Magnesium Retention

The interplay between calcium and magnesium is intricate. High-calcium additives can lead to significant changes in magnesium status, particularly if there is ongoing nutrient loss due to metabolic states. For instance, during periods of fasting or when patients experience phosphate-depletion syndrome, the relationship between these two electrolytes becomes even more pronounced. Essentially, the amounts of calcium supplied on a daily basis can influence magnesium levels, highlighting the need for careful monitoring during TPN administration.

Electrolyte Interaction Effects on Magnesium Observations
High calcium levels Decreased net magnesium retention Increased urine magnesium
Increased magnesium needs Potential need to adjust TPN formulation Dependent on metabolic state
Fasting state Altered magnesium metabolism Resulting in potential deficiencies

Overall, the balance between calcium and magnesium is essential for patient safety, particularly for those on long-term TPN.

Balancing Calcium and Phosphate in TPN Formulations

What is the major concern with the combination of calcium and phosphate in a TPN?

The major concern with the combination of calcium and phosphate in total parenteral nutrition (TPN) is the risk of calcium phosphate precipitation. This precipitation can occur when high concentrations of these elements are supplied and can lead to complications such as clogged intravenous lines. It's crucial to manage the ratios of calcium to phosphate vigilantly, as improper balancing may have adverse effects on patient health.

How can precipitation be prevented in TPN formulations?

To prevent precipitation of calcium and phosphate during TPN preparation, a number of strategies should be employed:

  • Order of Mixing: Always add phosphate first, followed by calcium near the end of compounding. This helps minimize the chances of precipitation occurring during the mixing process.
  • Use of Compatibility: Using d-fructose-1,6-diphosphate (FDP) as a phosphorus source can enhance compatibility and help to prevent precipitation while still meeting nutritional needs.
  • Monitoring Concentrations : Regular monitoring of serum electrolyte levels is crucial to tailor the exact amounts of calcium and phosphate included in the TPN. Specific adjustments based on the patient's condition can further reduce the risk of precipitation.

Understanding Calcium and Magnesium Interplay

Moreover, adjustments in calcium levels can also affect magnesium metabolism, highlighting the interplay between these minerals during TPN administration. Careful consideration of all factors will ensure that TPN formulations remain stable and effective for patient care.

Challenges in Pediatric TPN: Calcium and Magnesium

Pediatric Growth Needs

In pediatric patients, particularly newborns and preterm infants, the requirements for calcium and magnesium are intricately tied to growth and development. Calcium plays a crucial role in bone mineralization, while magnesium is essential for enzymatic functions and muscle performance. Optimal calcium intake is critical during rapid growth periods. For instance, the proposed requirements for neonates are between 1.0 and 4.0 mmol/kg/day for calcium, depending on their individual growth needs and health status.

Electrolyte Balance Importance

Maintaining electrolyte balance is vital for patients receiving Total Parenteral Nutrition (TPN). Calcium and magnesium are integral components of TPN formulations, and their adequate provision is necessary to prevent complications such as metabolic bone disease. Imbalances can lead to hypomagnesemia or hypermagnesemia, which can result in serious neuromuscular and cardiovascular issues.

Close monitoring of serum levels is essential to tailor the TPN mix to meet the specific needs of the pediatric patient, ensuring both safety and efficacy. Given the complexities of electrolyte management in TPN, clinicians must navigate dosing carefully, taking into account the child's overall health and underlying conditions.

Nutrient Recommended Daily Intake Main Functions
Calcium 1.0-4.0 mmol/kg/day for infants Bone health, muscle function
Magnesium 7-15 mEq/day; 15-45 mEq/day for positive balance Enzymatic reactions, CNS activity
Importance Critical for growth and metabolic balance Prevents neuromuscular complications

Clinical Implications of Calcium and Magnesium Deficiencies

Symptoms and Correction Procedures

Calcium and magnesium deficiencies can lead to a range of significant symptoms, making routine monitoring essential in patients on Total Parenteral Nutrition (TPN). Symptoms of magnesium deficiency, termed hypomagnesemia, include neuromuscular issues such as weakness, cramps, disorientation, and potentially severe manifestations like cardiac dysrhythmias. For calcium, deficiency can impact bone density and muscle function, illustrating its importance in overall metabolic processes.

To correct hypomagnesemia, it is common practice to increase the magnesium content of TPN solutions, typically not exceeding 12 mEq per liter or 36 mEq daily total. Similarly, calcium should be administered carefully, emphasizing forms that reduce precipitation risks, ensuring patient safety.

Monitoring Strategies

Effective monitoring strategies for these electrolytes are crucial. Careful tracking of serum magnesium and calcium levels helps anticipate deficiency or toxicity. Blood work should focus on relevant electrolytes, particularly during initial phases of TPN to prevent complications like refeeding syndrome, which might involve disturbing electrolyte balance.

In pediatric patients, who are particularly vulnerable, adjusting calcium and magnesium levels in TPN is critical as growth demands differ significantly. Overall, a systematic approach to monitoring and managing calcium and magnesium in TPN is a vital component of patient care.

Analyzing Calcium and Magnesium Levels in TPN

How are calcium and magnesium levels monitored in TPN?

The determination of calcium and magnesium levels in Total Parenteral Nutrition (TPN) is crucial for patient safety and preventing complications. One effective method employed is capillary electrophoresis coupled with contactless conductivity detection (CE-C4D) . This technique allows for the complete separation of calcium and magnesium from other cations in less than 4 minutes, offering a rapid and efficient approach for quality control in TPN formulations.

Why is monitoring important for safety?

Calcium and magnesium are vital electrolytes that support bone health, muscle function, and overall metabolic regulation. Accurate dosing is essential, especially in vulnerable populations such as pediatrics, where requirements can vary significantly based on growth rates and specific health conditions. Monitoring serum levels helps prevent deficiencies, which can result in symptoms ranging from neuromuscular issues to severe metabolic dysfunctions.

Table of Electrolyte Monitoring in TPN

Electrolyte Recommended Dosage Importance
Calcium 10 to 20 mEq/l Supports muscle contraction and coagulation
Magnesium 8 to 24 mEq/l Cofactor for enzymes and CNS activity
Monitoring Serum electrolyte levels Prevents complications like hypomagnesemia

In TPN formulations, both calcium and magnesium must be regularly monitored to safely manage their levels, optimizing the patients’ nutritional support while minimizing risks. Their interplay during TPN administration makes it essential for clinicians to pay close attention, ensuring a balanced and effective nutritional plan.

Ensuring Stability in TPN Formulations

The Role of Amino Acids and Glucose

In Total Parenteral Nutrition (TPN) formulations, amino acids (AAs) and glucose serve as foundational components. The concentration of AAs is crucial as it enhances the stability of lipid emulsions, which are essential for energy provision. However, care must be exercised when using acidic AAs, as they can induce instability in formula emulsions, thus increasing the risk of precipitate formation.

Additionally, glucose is a vital energy source but can affect lipid phase stability if present in high concentrations due to its acidic character. This calls for careful balancing of both amino acids and glucose in TPN to maintain efficacy while ensuring stability.

Environmental Factors Affecting Stability

The stability of calcium and magnesium in TPN is influenced by several environmental factors, particularly temperature and pH. Solubility of these minerals typically decreases with rising temperature and increases as pH lowers. Such factors must be accounted for to prevent undesirable precipitation, particularly calcium phosphate.

Furthermore, the order of addition during formulation is critical. Calcium should generally be added near the end of the mixing process, after phosphate, to minimize precipitation risk. Adopting proper mixing techniques is thus essential for maintaining the integrity of TPN formulations, ensuring that patients receive these vital nutrients without complications.

TPN Complications: Role of Calcium and Magnesium

What is the most common complication of total parenteral nutrition (TPN)?

The most common complications of total parenteral nutrition (TPN) include hyperglycemia and infections associated with the central venous catheters used for administration. Hyperglycemia can occur in up to 50% of TPN patients. It necessitates careful monitoring and management to prevent additional health issues, including altering metabolic state and increased energy needs.

Additionally, the risk of catheter-related infections can lead to severe conditions such as bloodstream infections and sepsis. These infections can significantly compromise patient health and require immediate medical intervention.

Other notable complications linked to TPN include refeeding syndrome, particularly in malnourished patients, which can induce electrolyte imbalances, specifically involving magnesium and calcium metabolism. Long-term TPN patients might also face liver problems, such as fatty liver and cholestasis; these issues are often exacerbated by deficiencies in essential minerals like calcium and magnesium.

Close monitoring of serum electrolytes, particularly calcium and magnesium levels, is essential for all TPN patients. Any derangement in these electrolytes can lead to complications impacting neuromuscular function and bone health, making it vital for clinicians to manage these minerals effectively during TPN therapy.

Optimizing Patient Outcomes with Calcium and Magnesium in TPN

What research findings highlight the importance of calcium and magnesium in TPN?

Calcium and magnesium are crucial electrolytes in Total Parenteral Nutrition (TPN) formulations, directly impacting bone health and neuromuscular function. Research indicates that calcium should be administered at a recommended dosage of 10 to 20 mEq per liter and magnesium at 8 to 24 mEq per liter of TPN. The interplay between these two electrolytes is significant; for example, excessive calcium can lead to hypomagnesemia, highlighting the necessity for balanced formulations.

Studies have shown that a proper calcium and magnesium ratio, such as an optimal 1.3:1 calcium to phosphorus ratio, is beneficial for ensuring effective absorption and utilization. Incorrect proportions can lead to complications, including metabolic bone diseases in pediatric populations who are especially vulnerable due to their rapid growth needs.

How can TPN solutions be tailored for individual patient needs?

Individualizing TPN solutions is essential for optimizing patient outcomes. This involves regular monitoring of serum calcium and magnesium levels to adjust dosages as necessary. For instance, in cases of hypomagnesemia, the magnesium content can be increased in the TPN solution, not exceeding a total of 36 mEq per day.

Furthermore, clinicians should consider factors such as age, nutritional state, and underlying health conditions that may affect electrolyte absorption and metabolism. For pediatric patients, specific dosages (1.0-4.0 mmol/kg/d for calcium and 0.75-3.0 mmol/kg/d for phosphorus) must be carefully calculated based on growth dynamics and health status, preventing deficiencies that could lead to significant clinical issues.

Table of Key Considerations in TPN Formulations for Calcium and Magnesium

Component Recommendation Clinical Significance
Calcium (Ca) 10-20 mEq/L Supports muscle function and bone health
Magnesium (Mg) 8-24 mEq/L Regulates enzymatic reactions and CNS activity
Calcium to Phosphorus Ratio 1.3:1 Enhances absorption efficiency
Monitoring Frequency Regular serum electrolyte checks Prevents deficiencies and complications

Conclusion: The Indispensable Role of Calcium and Magnesium in TPN

Calcium and magnesium are vital elements in TPN formulations, integral to maintaining physiological functions and preventing deficiencies in patients who cannot consume food orally. Understanding their roles, recommended levels, and interactions within TPN helps healthcare professionals optimize patient care and outcomes. Balancing these electrolytes effectively addresses compatibility and stability challenges, ensuring that TPN remains a safe and viable nutrition delivery method. As we continue to learn from clinical guidelines and research, tailoring these formulations becomes increasingly precise, especially for vulnerable populations, including pediatric patients.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More